Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.
- Publisher:
- Springer
- Publication Type:
- Journal Article
- Citation:
- Current Hypertension Reports, 2020, 22, (5), pp. 37-37
- Issue Date:
- 2020-04-14
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Suvakov, S | |
dc.contributor.author |
Richards, C https://orcid.org/0000-0001-5080-9164 |
|
dc.contributor.author | Nikolic, V | |
dc.contributor.author | Simic, T | |
dc.contributor.author |
McGrath, K https://orcid.org/0000-0002-6244-3929 |
|
dc.contributor.author | Krasnodembskaya, A | |
dc.contributor.author |
McClements, L https://orcid.org/0000-0002-4911-1014 |
|
dc.date.accessioned | 2021-06-04T06:34:44Z | |
dc.date.available | 2021-06-04T06:34:44Z | |
dc.date.issued | 2020-04-14 | |
dc.identifier.citation | Current Hypertension Reports, 2020, 22, (5), pp. 37-37 | |
dc.identifier.issn | 1522-6417 | |
dc.identifier.issn | 1534-3111 | |
dc.identifier.uri | http://hdl.handle.net/10453/149419 | |
dc.description.abstract | Purpose of Review Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia. Recent Findings MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects. Summary MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | Springer | |
dc.relation.ispartof | Current Hypertension Reports | |
dc.relation.isbasedon | 10.1007/s11906-020-1034-8 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1103 Clinical Sciences, 1115 Pharmacology and Pharmaceutical Sciences | |
dc.subject.mesh | Mesenchymal Stem Cells | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pre-Eclampsia | |
dc.subject.mesh | Hypertension | |
dc.subject.mesh | Inflammation | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Female | |
dc.subject.mesh | Mesenchymal Stem Cells | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pre-Eclampsia | |
dc.subject.mesh | Hypertension | |
dc.subject.mesh | Inflammation | |
dc.subject.mesh | Pregnancy | |
dc.subject.mesh | Female | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Hypertension | |
dc.subject.mesh | Inflammation | |
dc.subject.mesh | Mesenchymal Stem Cells | |
dc.subject.mesh | Pre-Eclampsia | |
dc.subject.mesh | Pregnancy | |
dc.title | Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia. | |
dc.type | Journal Article | |
utslib.citation.volume | 22 | |
utslib.location.activity | United States | |
utslib.for | 1103 Clinical Sciences | |
utslib.for | 1115 Pharmacology and Pharmaceutical Sciences | |
utslib.for | 1103 Clinical Sciences | |
utslib.for | 1115 Pharmacology and Pharmaceutical Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
pubs.consider-herdc | false | |
dc.date.updated | 2021-06-04T06:34:42Z | |
pubs.issue | 5 | |
pubs.publication-status | Published | |
pubs.volume | 22 | |
utslib.citation.issue | 5 |
Abstract:
Purpose of Review
Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia.
Recent Findings
MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects.
Summary
MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph